The molecular profile of patients in this study showed, that young women with endometrial cancer were classified as 19% MMR immunohistochemically abnormal, 13% POLE exonuclease domain mutations (EDM), 4% p53 abnormal, and 64% p53 wild type [65]. Here, POLE is linked to endometrial cancer.